---
title: "Pharmaceutical Manufacturing Industry Trends 2026"
description: "The biggest trends shaping US pharmaceutical manufacturing in 2026. API reshoring, continuous manufacturing, IRA drug pricing impact, cell and gene therapy, BIOSECURE Act, and supply chain resilience."
slug: pharmaceutical-manufacturing-industry-trends-2026
type: statistics
publishedAt: 2026-06-02
updatedAt: 2026-06-02
readingTime: "~11 min read"
keywords: "pharmaceutical manufacturing trends 2026, pharma industry trends, API reshoring, biopharmaceutical manufacturing, cell and gene therapy"
breadcrumb:
  - { name: "Home", href: "/" }
  - { name: "Pharmaceutical Manufacturing Industry Trends 2026", href: "/pharmaceutical-manufacturing-industry-trends-2026" }
linkPhrases:
  - "pharmaceutical manufacturing trends"
  - "pharma industry trends"
  - "pharmaceutical manufacturing"
related:
  - manufacturing-industry-trends-2026
  - medical-device-manufacturing-statistics
sources:
  - title: "Pharmaceutical and Medicine Manufacturing (NAICS 3254)"
    publisher: "US Bureau of Labor Statistics"
    year: "2024"
    url: "https://www.bls.gov/iag/tgs/iag3254.htm"
  - title: "US Pharmaceutical Manufacturing Industry"
    publisher: "International Trade Administration"
    year: "2024"
    url: "https://www.trade.gov/healthcare-industry-data"
  - title: "Inflation Reduction Act Drug Price Negotiation"
    publisher: "Centers for Medicare and Medicaid Services"
    year: "2025"
    url: "https://www.cms.gov/inflation-reduction-act-and-medicare"
  - title: "BIOSECURE Act"
    publisher: "US Congress"
    year: "2024"
    url: "https://www.congress.gov/"
  - title: "ASPR Industrial Base Analysis"
    publisher: "Administration for Strategic Preparedness and Response"
    year: "2024"
    url: "https://aspr.hhs.gov/"
  - title: "FDA Office of Pharmaceutical Quality"
    publisher: "US Food and Drug Administration"
    year: "2024"
    url: "https://www.fda.gov/about-fda/center-drug-evaluation-and-research/office-pharmaceutical-quality"
---

<UpdatedDate date="2026-06-02" readingTime="~11 min read" />

US pharmaceutical manufacturing entered 2026 navigating the most disruptive policy and supply chain shifts in modern industry history. The Inflation Reduction Act drug-pricing program has changed how 10 high-spend drugs are priced for Medicare, with implications cascading across the sector. The BIOSECURE Act is reshaping which Chinese biotech contract partners US companies can work with. API reshoring has finally gained meaningful momentum after a decade of policy attention. Cell and gene therapy manufacturing is moving from boutique to scaled production.

<KeyTakeaways>

- US pharmaceutical and medicine manufacturing generates approximately $625B in annual shipments, the largest globally.
- Direct US pharma manufacturing employment exceeds 320,000, with another 1.5M+ in supplier and supporting roles.
- The IRA drug price negotiation program took effect for the first 10 drugs in 2026.
- Active pharmaceutical ingredient (API) reshoring has accelerated through 2024 to 2025, supported by BARDA, ASPR, and tax incentives.
- The BIOSECURE Act, signed in late 2024, restricts federal-funded relationships with named Chinese biotech contract organizations.

</KeyTakeaways>

## How large is US pharmaceutical manufacturing in 2026?

<StatSnippet value="$625B" source="ITA, 2024" sourceUrl="https://www.trade.gov/healthcare-industry-data">
US pharmaceutical and medicine manufacturing annual shipments, the largest country-level pharma manufacturing sector globally.
</StatSnippet>

<StatSnippet value="320K+" source="BLS, 2024" sourceUrl="https://www.bls.gov/iag/tgs/iag3254.htm">
Direct US pharmaceutical manufacturing employment as of 2024, with growth in cell and gene therapy and reshored API capacity.
</StatSnippet>

The US pharmaceutical industry sits atop the global pharma manufacturing landscape by revenue, R&D investment, and workforce. Beyond the direct manufacturing footprint, the industry supports a large supplier ecosystem including bulk chemical and reagent producers, packaging specialists, contract manufacturing organizations (CMOs), contract development and manufacturing organizations (CDMOs), and sterile fill-finish providers.

The geographic concentration favors Pennsylvania, New Jersey, North Carolina, Massachusetts, California, Puerto Rico, and Indiana. Puerto Rico in particular remains a major pharmaceutical manufacturing hub despite the long-term post-Hurricane Maria recovery, with several major OEMs continuing to invest there.

## How is API reshoring progressing in 2026?

<StatSnippet value="80%+" source="ASPR Industrial Base Analysis, 2024" sourceUrl="https://aspr.hhs.gov/">
Estimated share of US generic drug API supply that originates from facilities in China and India as of recent FDA registration data.
</StatSnippet>

API (active pharmaceutical ingredient) reshoring has been a policy priority for a decade, but the practical momentum has accelerated sharply since 2022. BARDA grants, ASPR industrial base programs, IRA tax credits, and bipartisan congressional concern about supply chain security have all combined to fund and de-risk new US API capacity.

Notable 2023 to 2025 API reshoring projects include continuous manufacturing facilities for essential medicines, expansions at Civica Rx and partnered manufacturers, capacity additions at major contract API producers, and federal-backed expansion of US sterile fill-finish capacity. The total announced investment in US API and biologics manufacturing capacity since 2022 exceeds $15 billion.

Despite progress, the structural dependency is real. The vast majority of US generic drug APIs still originate in China or India. Full domestic redundancy for the 200-plus essential medicines list would require many more years and tens of billions in continued investment.

## What is the impact of the Inflation Reduction Act on pharma manufacturing?

The IRA drug price negotiation program took effect for the first 10 selected drugs on January 1, 2026. The selected drugs (including Eliquis, Jardiance, Xarelto, Januvia, Imbruvica, Farxiga, Enbrel, Stelara, Entresto, Fiasp/Novolog) collectively represent over $50 billion in annual Medicare spending before the negotiated prices took effect.

For manufacturers, the program creates several pressure points. Revenue compression on the negotiated drugs reduces the cash flow available for R&D and capacity investment. Pricing dynamics on adjacent products in the same therapeutic categories shift. Investment decisions for new drug development tilt toward areas less likely to enter near-term negotiation cycles. The longer-term effect on US pharmaceutical innovation funding is debated heavily among industry analysts.

<DataTable caption="IRA drug price negotiation program timeline">

| Year | Number of negotiated drugs | Notes                                              |
| ---: | -------------------------: | -------------------------------------------------- |
| 2026 | 10                         | First negotiated prices in effect (Medicare Part D)|
| 2027 | 15                         | Includes Part B drugs starting this year           |
| 2028 | 15                         | Continued expansion                                |
| 2029+ | Up to 20/year             | Ongoing annual expansion                           |

</DataTable>

<InlineCTA title="See where AI search puts your pharma operation" body="Procurement teams at major pharma OEMs use AI assistants to research CMOs and specialty suppliers. Run a free check to see how your domain currently shows up." source="pharma-trends-mid" />

## How is the BIOSECURE Act reshaping CDMO relationships?

The BIOSECURE Act, signed in late 2024, restricts federal funding from being used for biotech equipment and services from named Chinese companies, including WuXi AppTec, WuXi Biologics, BGI, MGI, and Complete Genomics. Phased implementation allows existing contracts to wind down through 2032, but new federal-funded relationships are restricted immediately.

For US biopharma companies, the practical effect is shifting some CDMO and CRO work away from named Chinese partners. The displaced work creates significant opportunity for US-based and European-based CDMOs serving similar functions. Capacity expansion at Catalent, Lonza, Samsung Biologics (US sites), Recipharm, Patheon (Thermo Fisher), and several smaller CDMOs is underway in response.

## How is continuous manufacturing changing pharma production?

Continuous manufacturing has moved from research interest to commercial reality over the past decade. The FDA has approved multiple drugs manufactured continuously rather than in batch mode, including Janssen's Prezista and Vertex's Orkambi. The technology offers better quality control, smaller facility footprints, and the ability to scale output without traditional batch-validation cycles.

Adoption remains uneven. Large molecule biologics and complex sterile products still rely on batch processing for most applications. Small molecule oral solid dosage forms have seen the broadest continuous-manufacturing adoption. The FDA's Office of Pharmaceutical Quality has actively encouraged continuous-mode applications, which has reduced the regulatory uncertainty that slowed adoption in the 2010s.

## What is happening to cell and gene therapy manufacturing?

<StatSnippet value="40+" source="FDA, 2024" sourceUrl="https://www.fda.gov/about-fda/center-drug-evaluation-and-research/office-pharmaceutical-quality">
Approved cell and gene therapy products in the United States as of late 2024, up from approximately 10 in 2020.
</StatSnippet>

Cell and gene therapy manufacturing has scaled from laboratory-scale toward industrial production. Approved therapies span CAR-T cancer treatments, gene therapies for inherited conditions, regenerative medicine, and several rare disease products. Manufacturing is highly specialized, with each therapy effectively a distinct manufacturing process, but the cumulative production volume is now meaningful.

Major US cell and gene therapy manufacturing sites operate in Massachusetts, North Carolina, California, Indiana, and Pennsylvania. CDMOs supporting this segment have invested heavily in viral vector manufacturing capacity, autologous cell processing, plasmid DNA production, and specialized fill-finish capabilities.

<StatGrid>
  <StatCard value="40+" label="Approved cell and gene therapy products in US" source="FDA, 2024" />
  <StatCard value="$10B+" label="Estimated annual US cell and gene therapy market" source="Industry estimates, 2024" />
  <StatCard value="500+" label="Active US cell and gene therapy clinical trials" source="ClinicalTrials.gov, 2024" />
</StatGrid>

## How is the FDA shaping pharma manufacturing in 2026?

FDA Office of Pharmaceutical Quality has continued tightening enforcement on manufacturing quality issues, with several major facility warning letters and import alerts issued in 2024 and 2025. The agency has also published updated guidance on continuous manufacturing, advanced therapeutic medicinal products, and elemental impurities.

For US manufacturers, the FDA's posture creates both opportunity and burden. Quality issues at competitor facilities (including high-profile shortage events) create market openings for US-based producers with strong inspection histories. The compliance bar continues to rise, particularly around data integrity, supplier qualification, and process validation.

## What is the pharmaceutical manufacturing outlook for 2026?

US pharmaceutical manufacturing in 2026 sits at the intersection of strong structural tailwinds and meaningful policy headwinds. The tailwinds: reshoring momentum, BIOSECURE-driven CDMO opportunity, cell and gene therapy growth, FDA support for advanced manufacturing techniques, and a continued biopharma innovation pipeline. The headwinds: IRA pricing pressure on Medicare-negotiated drugs, regulatory complexity, ongoing API supply chain dependency, and capital cost from elevated interest rates.

For pharmaceutical contract manufacturers, sterile fill-finish specialists, packaging suppliers, and equipment providers, the competitive picture rewards specialization, validated quality systems, and visible US workforce stability. Pharma OEMs increasingly select CDMO partners based on demonstrated quality history, capacity in specific dosage forms, and supply chain resilience.

<Callout type="tip" title="Where to go from here">

For US-wide trends across all manufacturing, see [manufacturing industry trends 2026](/manufacturing-industry-trends-2026). For the closely related medical devices sector, see [medical device manufacturing statistics](/medical-device-manufacturing-statistics). To see how AI search currently describes your pharma manufacturing operation, run a [free AI-visibility check](/checker).

</Callout>

<CiteBox title="Pharmaceutical Manufacturing Industry Trends 2026" url="https://manufacturingseo.ai/pharmaceutical-manufacturing-industry-trends-2026" citation={`Manufacturing SEO AI. "Pharmaceutical Manufacturing Industry Trends 2026." Manufacturing SEO AI, June 2026. https://manufacturingseo.ai/pharmaceutical-manufacturing-industry-trends-2026`} />